Archive · 24 Jul 2025
Tulsi Therapeutics Achieves Breakthrough in Liver Failure Therapy
Scientists have created a new treatment called Tulsi-28X for people with liver problems.
This treatment uses special cells and tiny messengers called exosomes to help the liver heal itself.
In animal tests, the treatment worked very well, helping the animals’ livers get better and preventing deaths.
The research was done in India with the help of scientists from around the world.
Now, they are planning to test the treatment on people to see if it can help them too, which could offer a new way to treat liver problems.
Tulsi Therapeutics completed successful pre-clinical trials for a stem cell-exosome therapy for liver failure.
The therapy, Tulsi-28X, is derived from Wharton’s Jelly mesenchymal stem cells and their native exosomes.
The animal trial showed 100% reversal of liver fibrosis in treated animals, with zero deaths.
The study was conducted in collaboration with global experts and presented at the AASLD 2024 Liver Conference.
Human clinical trials are planned in collaboration with Nizam’s Institute of Medical Sciences (NIMS).
- Who
- Tulsi Therapeutics, in collaboration with experts and institutions like ASPIRE-BioNEST at the University of Hyderabad.
- What
- Successful pre-clinical trials of a stem cell-exosome therapy for chronic liver failure, called Tulsi-28X.
- When
- The trials were recently completed, with results presented at AASLD 2024 and published in the Journal of Regenerative Medicine.
- Where
- The research was conducted in India, with collaborations from experts in the US.
- Why
- To develop a new treatment for chronic liver failure, addressing a significant global health concern.
Current Treatments
New Therapy
Treatment Options
Current Treatments
The only current treatment for chronic liver failure is transplantation.
New Therapy
The newly developed therapy provides a novel treatment option.
- Therapy Name
- Tulsi-28X
- Treatment Type
- Stem cell-exosome therapy
- Origin
- Developed in India
- Trial Results
- 100% reversal of liver fibrosis in animals
- Next Steps
- Human clinical trials planned
- Collaborating Institution
- Nizam’s Institute of Medical Sciences (NIMS)